SCHEMBL22979197

SCHEMBL22979197

COc1cccc(-c2nc3c4ccccc4nc(Cl)n3n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
CYP1A2 P05177 6/20 0.55
CYP3A4 P08684 6/20 0.55
CYP2C9 P11712 3/20 0.55
CYP2B6 P20813 2/20 0.55
AHR P35869 2/20 0.55
NR1I3 Q14994 2/20 0.55
VDR P11473 1/20 0.55
CYP2D6 P10635 5/20 0.52
USP2 O75604 3/20 0.52
MAPK1 P28482 3/20 0.52
CLK4 Q9HAZ1 3/20 0.52
ALOX15 P16050 2/20 0.52
CYP2C19 P33261 2/20 0.52
HSD17B10 Q99714 2/20 0.52
THRB P10828 2/20 0.52
TSHR P16473 3/20 0.50
ADORA3 P0DMS8 2/20 0.50
LMNA P02545 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646448 1.00 MAPT (0.57) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL22987485 0.87 MAPT (0.52) MAPTSMN1; SMN2HSD17B10THRBADORA3
SCHEMBL22987469 0.87 MAPT (0.52) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL29646439 0.86 ADORA3 (0.65) MAPTCYP1A2THRBADORA3ALDH1A1
SCHEMBL22979306 0.86 ADORA3 (0.65) MAPTCYP1A2THRBADORA3ALDH1A1
SCHEMBL22987471 0.86 MAPT (0.45) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL22987875 0.86 MAPT (0.45) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL22979767 0.85 ADORA3 (0.47) MAPTSMN1; SMN2THRBADORA3TP53
SCHEMBL29646340 0.85 ADORA3 (0.47) MAPTSMN1; SMN2THRBADORA3TP53
SCHEMBL22980034 0.84 RXFP1 (0.61) MAPTSMN1; SMN2NR1I3MAPK1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 MAPT 4047/4885SMN1; SMN2 4234/4885CYP1A2 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.